{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:25Z","timestamp":1793908045047,"version":"4.8.0"},"reference-count":49,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<p>The management of low-density lipoprotein cholesterol (LDL-C) levels is a central strategy for the prevention of atherosclerotic cardiovascular disease. Current United States (2018 American Heart Association\/American College of Cardiology\/Multisociety) and European (2019 European Society of Cardiology\/European Atherosclerosis Society) guidelines endorse statin therapy as the first-line therapy for pharmacologic LDL-C lowering. However, in clinical practice up to 30% of patients report partial or complete intolerance to statin therapy. While the nocebo effect with statins is well described, perceived statin intolerance prevents many patients from achieving LDL-C thresholds associated with clinical benefit. Bempedoic acid is a novel, oral, non-statin lipid-lowering therapy that works by inhibiting adenosine triphosphate-citrate lyase, an enzymatic reaction upstream of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the hepatic cholesterol synthesis pathway. Bempedoic acid confers reduction in LDL-C of ~18% on background statin therapy,~21% in patients with statin intolerance, and ~38% when given in fixed-dose combination with ezetimibe. The CLEAR Outcomes trial, which enrolled high-risk primary and secondary prevention patients with reported statin intolerance and LDL-C levels =100 mg\/dL, showed that bempedoic acid compared with placebo reduced 4-component major adverse cardiovascular events (MACE) by 13% (hazard ratio 0.87, 95% confidence interval 0.79\ufffd0.96). Bempedoic acid also reduced 3-component MACE by 15%, myocardial infarction by 23% and coronary revascularization by 19%. The benefit was even greater in the primary prevention cohort (hazard ratio 0.70, 95% confidence interval 0.55\ufffd0.89) for 4-component MACE. Bempedoic acid was associated with increases in uric acid levels and cholelithiasis, but numerically fewer events of myalgia and new-onset diabetes. These findings confirm that bempedoic acid is an effective approach to reduce cardiovascular outcomes in high-risk patients with statin intolerance who require further reduction in LDL-C.<\/p>","DOI":"10.17925\/hi.2023.17.2.1","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T15:33:33Z","timestamp":1701358413000},"page":"1","source":"Crossref","is-referenced-by-count":14,"title":["Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention"],"prefix":"10.17925","volume":"17","author":[{"given":"Michael","family":"Albosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Internal Medicine Department, University of Miami Miller School of Medicine\/Jackson Memorial Hospital, Miami, FL, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelani K","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D","family":"Michos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: A report from the American Heart Association.\n                      Circulation\n                      . 2023;147:e93\ufffd621. DOI: 10.1161\/CIR.0000000000001123.","DOI":"10.1161\/CIR.0000000000001137"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.\n                      Eur Heart J\n                      . 2017;38:2459\u201372. DOI: 10.1093\/eurheartj\/ehx144.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series.\n                      J Am Coll Cardiol\n                      . 2018;72:2980\u201395. DOI: 10.1016\/j.jacc.2018.10.021.","DOI":"10.1016\/j.jacc.2018.10.021"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, et al. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.\n                      Eur Heart J\n                      . 2020;41:111\u201388. DOI: 10.1093\/eurheartj\/ehz455.","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/Apha\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.\n                      Circulation\n                      . 2019;139:e1082\u2013143. DOI: 10.1161\/CIR.0000000000000625.","DOI":"10.1161\/CIR.0000000000000699"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists Collaboration, Fulcher J. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomized trials.\n                      Lancet\n                      . 2015;385:1397-405. DOI: 10.1016\/S0140-6736(14)61368-4.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Collaboration CTT, Baigent C, Blackwell L. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials.\n                      Lancet\n                      . 2010;376:1670\u201381. DOI: 10.1016\/S0140-6736(10)61350-5.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: Impact on statin therapy European Atherosclerosis Society consensus panel statement on assessment.\n                      Eur Heart J\n                      . 2015;36:1012\u201322. DOI: 10.1093\/eurheartj\/ehv043.","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: A scientific statement from the American heart association.\n                      Arterioscler Thromb Vasc Biol\n                      . 2019;39:e38\u201381. DOI: 10.1161\/ATV.0000000000000073.","DOI":"10.1161\/ATV.0000000000000081"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: A new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.\n                      J Clin Lipidol\n                      . 2022;16:361\u201375. DOI: 10.1016\/j.jacl.2022.05.068.","DOI":"10.1016\/j.jacl.2022.05.068"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease.\n                      JAMA Cardiol\n                      . 2019;4:206\u201313. DOI: 10.1001\/jamacardio.2018.4936.","DOI":"10.1001\/jamacardio.2018.4936"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Khunti K, Danese MD, Kutikova L, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe.\n                      JAMA Netw Open\n                      . 2018;1:e185554. DOI: 10.1001\/jamanetworkopen.2018.5554.","DOI":"10.1001\/jamanetworkopen.2018.5554"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review.\n                      Br J Clin Pharmacol\n                      . 2014;78:684\u201398. DOI: 10.1111\/bcp.12339.","DOI":"10.1111\/bcp.12339"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: A meta-analysis.\n                      Eur Heart J\n                      . 2022;43:3213\u201323. DOI: 10.1093\/eurheartj\/ehac015.","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo and no treatment.\n                      J Am Coll Cardiol\n                      . 2021;78:1210\u201322. DOI: 10.1016\/j.jacc.2021.07.022.","DOI":"10.1016\/j.jacc.2021.07.022"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology solution set oversight committee.\n                      J Am Coll Cardiol\n                      . 2022;80:1366\u2013418. DOI: 10.1016\/j.jacc.2022.07.006.","DOI":"10.1016\/j.jacc.2022.07.006"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pinkosky SL, Filippov S, Srivastava RAK, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.\n                      J Lipid Res\n                      . 2013;54:134\u201351. DOI: 10.1194\/jlr.M030528.","DOI":"10.1194\/jlr.M030528"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.\n                      N Engl J Med\n                      . 2023;388:1353\u201364. DOI: 10.1056\/NEJMoa2215024.","DOI":"10.1056\/NEJMoa2215024"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Oroko M, Fisher M. Bempedoic acid.\n                      Practical Diabetes\n                      . 2022;39:42\u20133a. DOI: 10.1002\/pdi.2380.","DOI":"10.1002\/pdi.2380"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.\n                      Nat Commun\n                      . 2016;7:13457. DOI: 10.1038\/ncomms13457.","DOI":"10.1038\/ncomms13457"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolaemia: From bench to bedside.\n                      Drug Des Devel Ther\n                      . 2021;15:1955\u201363. DOI: 10.2147\/DDDT.S251865.","DOI":"10.2147\/DDDT.S251865"},{"key":"ref22","unstructured":"Nexletol (Bempedoic acid). Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf (Date last accessed: 7 April 2023)."},{"key":"ref23","unstructured":"Nexlizet (Bempedoic acid and Ezetimibe). Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211617s000lbl.pdf (Date last accessed: 7 April 2023)."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy.\n                      Circulation\n                      . 2003;107:3124\u20138. DOI: 10.1161\/01.CIR.0000072345.98581.24.","DOI":"10.1161\/01.CIR.0000072345.98581.24"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolaemia: A randomized, placebo-controlled study.\n                      Atherosclerosis\n                      . 2018;277:195\u2013203. DOI: 10.1016\/j.atherosclerosis.2018.06.002.","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Khan SU, Michos ED. Bempedoic acid and ezetimibe better together.\n                      Eur J Prev Cardiolog\n                      . 2020;27:590\u20132. DOI: 10.1177\/2047487319864672.","DOI":"10.1177\/2047487319864672"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolaemia: Results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial.\n                      J Am Coll Cardiol\n                      . 2013;62:1154\u201362. DOI: 10.1016\/j.jacc.2013.05.050.","DOI":"10.1016\/j.jacc.2013.05.050"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolaemic patients receiving statin therapy.\n                      Am J Cardiol\n                      . 2016;117:1928\u201333. DOI: 10.1016\/j.amjcard.2016.03.043.","DOI":"10.1016\/j.amjcard.2016.03.043"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolaemic patients with or without statin intolerance.\n                      J Clin Lipidol\n                      . 2016;10:556\u201367. DOI: 10.1016\/j.jacl.2015.12.025.","DOI":"10.1016\/j.jacl.2015.12.025"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol.\n                      N Engl J Med\n                      . 2019;380:1022\u201332. DOI: 10.1056\/NEJMoa1803917.","DOI":"10.1056\/NEJMoa1803917"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR wisdom randomized clinical trial.\n                      JAMA\n                      . 2019;322:1780\u20138. DOI: 10.1001\/jama.2019.16585.","DOI":"10.1001\/jama.2019.16585"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolaemia and statin intolerance.\n                      J Am Heart Assoc\n                      . 2019;8:e011662. DOI: 10.1161\/JAHA.118.011662.","DOI":"10.1161\/JAHA.118.011662"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Banach M, Bays HE, et al. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolaemia (from the CLEAR harmony open-label extension study).\n                      Am J Cardiol\n                      . 2022;174:1\u201311. DOI: 10.1016\/j.amjcard.2022.03.020.","DOI":"10.1016\/j.amjcard.2022.03.020"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolaemia and high CVD risk treated with maximally tolerated statin therapy.\n                      Eur J Prev Cardiol\n                      . 2020;27:593\u2013603. DOI: 10.1177\/2047487319864671.","DOI":"10.1177\/2047487319864671"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: Pooled data from four phase III clinical trials.\n                      J Clin Lipidol\n                      . 2020;14:649\u201359. DOI: 10.1016\/j.jacl.2020.08.009.","DOI":"10.1016\/j.jacl.2020.08.009"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomized statin trials.\n                      Lancet\n                      . 2010;375:735\u201342. DOI: 10.1016\/S0140-6736(09)61965-6.","DOI":"10.1016\/S0140-6736(10)60991-9"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Leiter LA, Banach M, Catapano AL, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase III clinical trials.\n                      Diabetes Obesity Metabolism\n                      . 2022;24:868\u201380. DOI: 10.1111\/dom.14645.","DOI":"10.1111\/dom.14645"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients.\n                      JAMA\n                      . 2023;330:131\u201340. DOI: 10.1001\/jama.2023.9696.","DOI":"10.1001\/jama.2023.9696"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Khan SU, Raghu Subramanian C, Khan MZ, et al. Association of women authors with women enrollment in clinical trials of atrial fibrillation.\n                      J Am Heart Assoc\n                      . 2022;11:e024233. DOI: 10.1161\/JAHA.121.024233.","DOI":"10.1161\/JAHA.121.024233"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: A systematic review.\n                      JAMA Netw Open\n                      . 2020;3:e205202. DOI: 10.1001\/jamanetworkopen.2020.5202.","DOI":"10.1001\/jamanetworkopen.2020.5202"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Agarwala A, Goldberg A. Special considerations for lipid-lowering therapy in women reflecting recent randomized trials.\n                      Curr Atheroscler Rep\n                      . 2021;23:42. DOI: 10.1007\/s11883-021-00942-3.","DOI":"10.1007\/s11883-021-00942-3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Karalis DG, Wild RA, Maki KC, et al. Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in patient education (USAGE) study.\n                      J Clin Lipidol\n                      . 2016;10:833\u201341. DOI: 10.1016\/j.jacl.2016.02.016.","DOI":"10.1016\/j.jacl.2016.02.016"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice.\n                      Circ Cardiovasc Qual Outcomes\n                      . 2019;12:e005562. DOI: 10.1161\/CIRCOUTCOMES.118.005562.","DOI":"10.1161\/CIRCOUTCOMES.118.005562"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Ridker PM, Lei L, Ray KK, et al. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(A) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial.\n                      J Clin Lipidol\n                      . 2023;17:297\u2013302. DOI: 10.1016\/j.jacl.2023.02.002.","DOI":"10.1016\/j.jacl.2023.02.002"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Keaney JF. Bempedoic acid and the prevention of cardiovascular disease.\n                      N Engl J Med\n                      . 2023;388:1427\u201330. DOI: 10.1056\/NEJMe2300793.","DOI":"10.1056\/NEJMe2300793"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Banach M, Rizzo M, Toth PP, et al. Statin intolerance: An attempt at a unified definition position paper from an international lipid expert panel.\n                      Arch Med Sci\n                      . 2015;11:1\u201323. DOI: 10.5114\/aoms.2015.49807.","DOI":"10.5114\/aoms.2015.49807"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Markham A. Bempedoic acid: First approval.\n                      Drugs\n                      . 2020;80:747\u201353. DOI: 10.1007\/s40265-020-01308-w.","DOI":"10.1007\/s40265-020-01308-w"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Jadhav SB, Crass RL, Chapel S, et al. Pharmacodynamic effect of bempedoic acid and statin combinations: Predictions from a dose-response model.\n                      Atherosclerosis\n                      . 2021;331:e253. DOI: 10.1016\/j.atherosclerosis.2021.06.774.","DOI":"10.1016\/j.atherosclerosis.2021.06.774"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Yu D, Liao JK. Emerging views of statin pleiotropy and cholesterol lowering.\n                      Cardiovasc Res\n                      . 2022;118:413\u201323. DOI: 10.1093\/cvr\/cvab032.","DOI":"10.1093\/cvr\/cvab032"}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/cardiovascular-disease\/journal-articles\/bempedoic-acid-lipid-lowering-for-cardiovascular-disease-prevention\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:10Z","timestamp":1764745090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/cardiovascular-disease\/journal-articles\/bempedoic-acid-lipid-lowering-for-cardiovascular-disease-prevention\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["HI.2023.17.2.1"],"URL":"https:\/\/doi.org\/10.17925\/hi.2023.17.2.1","relation":{},"ISSN":["2036-2579"],"issn-type":[{"value":"2036-2579","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}